18F-fluorodeoxyglucose positron emission computed tomography for monitoring tumor response in esophageal carcinoma treated with concurrent chemoradiotherapy

Zhang,Peiliang; Li,Zengyun; Wang,Dongqing; Ma,Fuling; Zhang,Ran; Liang,Wanhua; Sun,Mingping; Fu,Zheng; Sun,Xiaorong

doi:10.3892/ol.2017.7528

18F-fluorodeoxyglucose positron emission computed tomography for monitoring tumor response in esophageal carcinoma treated with concurrent chemoradiotherapy

Authors:
- Peiliang Zhang
- Zengyun Li
- Dongqing Wang
- Fuling Ma
- Ran Zhang
- Wanhua Liang
- Mingping Sun
- Zheng Fu
- Xiaorong Sun
View Affiliations

Affiliations: Department of Radiation Oncology, Linyi Central Hospital, Yishui, Linyi, Shandong 276400, P.R. China, Department of Oncology, Laiwu Municipal Hospital of Traditional Chinese Medicine, Laiwu, Shandong 271100, P.R. China, Department of Radiation Oncology, Shandong Tumor Hospital, Jinan, Shandong 250117, P.R. China, Department of Nuclear Medicine, Shandong Tumor Hospital, Jinan, Shandong 250117, P.R. China
Published online on: December 5, 2017 https://doi.org/10.3892/ol.2017.7528
Pages: 1845-1852

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to explore the value of 18F-fluorodeoxyglucose positron emission tomography (18F‑FDG PET) in monitoring the early tumor response of esophageal squamous cell carcinoma (ESCC) treated with concurrent chemoradiotherapy (CRT). A total of 48 patients with pathologically proven ESCC were retrospectively analyzed. All patients underwent two serial 18F‑FDG PET scans at baseline (pre‑CRT) and 40 Gy/4 weeks of starting radiation therapy (inter‑CRT). All patients received intensity‑modulated radiotherapy (with a total radiation dose of 59.6 Gy) concurrently with cisplatin‑based chemotherapy. The maximum standardized uptake value (SUVmax) and metabolic tumor volume (MTV) were measured using 18F‑FDG PET. The percentage changes (Δ) in SUVmax and MTV between two serial scans were calculated and were revealed to be associated with the objective tumor response (oTR), according to the Response Evaluation Criteria in Solid Tumors 1.1. Among the 48 patients, 20.8% achieved a complete response, 68.8% exhibited a partial response and the oTR rate was 89.6%. On the pre‑CRT PET scans, the mean SUVmax and MTV were 14.1±5.8 and 58.2±25.4 cm3, respectively. Following 40 Gy irradiation over 4 weeks, the mean SUVmax and MTV significantly decreased to 4.3±3.5 and 19.0±12.1 cm3, respectively (P<0.001). A significantly higher ΔSUVmax and ΔMTV was observed in the responders compared with that in the non‑responders [0.71±0.16 vs. 0.51±0.26 (P=0.015); and 0.64±0.13 vs. 0.42±0.09 (P=0.001), respectively]. Univariate analysis revealed that ΔSUVmax and ΔMTV were signiﬁcantly associated with oTR (P=0.010 and P=0.001, respectively). ΔMTV was used as a predictor and a cut‑off value of 54% discriminated responders from non‑responders with a sensitivity of 69.8% and a specificity of 100% (P=0.001). The area under the receiver operating characteristic curve was 0.837 (95% confidence interval, 0.702‑0.928). The results of the present study indicated that interim 18F‑FDG PET scans may provide early prognostic value for determining oTR in patients with ESCC undergoing treatment with CRT.

View Figures

View References

1	Chen W, He Y, Zheng R, Zhang S, Zeng H, Zou X and He J: Esophageal cancer incidence and mortality in China, 2009. J Thorac Dis. 5:19–26. 2013.PubMed/NCBI
2	Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, et al: Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation therapy oncology group. JAMA. 281:1623–1627. 1999. View Article : Google Scholar : PubMed/NCBI
3	Ajani J, Bekaii-Saab T, D'Amico TA, Fuchs C, Gibson MK, Goldberg M, Hayman JA, Ilson DH, Javle M, Kelley S, et al: Esophageal cancer clinical practice guidelines. J Natl Compr Canc Netw. 4:328–347. 2006. View Article : Google Scholar : PubMed/NCBI
4	Wieder HA, Ott K, Lordick F, Becker K, Stahl A, Herrmann K, Fink U, Siewert JR, Schwaiger M and Weber WA: Prediction of tumor response by FDG-PET: Comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction. Eur J Nucl Med Mol Imaging. 34:1925–1932. 2007. View Article : Google Scholar : PubMed/NCBI
5	Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, Lorenzen S, Schuster T, Wieder H, Herrmann K, et al: PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: The MUNICON phase II trial. Lancet Oncol. 8:797–705. 2007. View Article : Google Scholar : PubMed/NCBI
6	Kim SJ, Koo PJ and Chang S: Predictive value of repeated F-18 FDG PET/CT parameters changes during preoperative chemoradiotherapy to predict pathologic response and overall survival in locally advanced esophageal adenocarcinoma patients. Cancer Chemother Pharmacol. 77:723–731. 2016. View Article : Google Scholar : PubMed/NCBI
7	Wieder HA, Brücher BL, Zimmermann F, Becker K, Lordick F, Beer A, Schwaiger M, Fink U, Siewert JR, Stein HJ and Weber WA: Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol. 22:900–908. 2004. View Article : Google Scholar : PubMed/NCBI
8	Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA, Cox JD, Komaki RR, Hong D, Lee HK, et al: 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer. 101:1776–1785. 2004. View Article : Google Scholar : PubMed/NCBI
9	Vali FS, Nagda S, Hall W, Sinacore J, Gao M, Lee SH, Hong R, Shoup M and Emami B: Comparison of standardized uptake value-based positron emission tomography and computed tomography target volumes in esophageal cancer patients undergoing radiotherapy. Int J Radiat Oncol Biol Phys. 78:1057–1063. 2010. View Article : Google Scholar : PubMed/NCBI
10	Jeganathan R, McGuigan J, Campbell F and Lynch T: Does pre-operative estimation of oesophageal tumour metabolic length using 18F-fluorodeoxyglucose PET/CT images compare with surgical pathology length? Eur J Nucl Med Mol Imaging. 38:656–662. 2011. View Article : Google Scholar : PubMed/NCBI
11	Wahl RL, Jacene H, Kasamon Y and Lodge MA: From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med. 50 Suppl 1:122S–150S. 2009. View Article : Google Scholar : PubMed/NCBI
12	Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: From the AJCC cancer staging manualAJCC Cancer Staging Handbook. 7th. Springer; New York, NY: 2010
13	Elimova E, Wang X, Etchebehere E, Shiozaki H, Shimodaira Y, Wadhwa R, Planjery V, Charalampakis N, Blum MA, Hofstetter W, et al: 18F-FDG PET/CT as predictive of response after chemoradiation in esophageal cancer patients. Eur J Cancer. 51:2545–2552. 2015. View Article : Google Scholar : PubMed/NCBI
14	Findlay JM, Middleton MR and Tomlinson I: A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage. Ann Oncol. 26:624–644. 2015. View Article : Google Scholar : PubMed/NCBI
15	Sato Y, Motoyama S, Saito H and Minamiya Y: Novel candidate biomarkers of chemoradiosensitivity in esophageal squamous cell carcinoma: A systematic review. Eur Surg Res. 56:141–153. 2016. View Article : Google Scholar : PubMed/NCBI
16	Monjazeb AM, Riedlinger G, Aklilu M, Geisinger KR, Mishra G, Isom S, Clark P, Levine EA and Blackstock AW: Outcomes of patients with esophageal cancer staged with [18F]fluorodeoxyglucose positron emission tomography (FDG-PET): Can postchemoradiotherapy FDG-PET predict the utility of resection? J Clin Oncol. 28:4714–4721. 2010. View Article : Google Scholar : PubMed/NCBI
17	Yuan H, Tong DK, Vardhanabhuti V, Law SY, Chiu KW and Khong PL: PET/CT in the evaluation of treatment response to neoadjuvant chemoradiotherapy and prognostication in patients with locally advanced esophageal squamous cell carcinoma. Nucl Med Commun. 37:947–955. 2016. View Article : Google Scholar : PubMed/NCBI
18	Chhabra A, Ong LT, Kuk D, Ku G, Ilson D, Janjigian YY, Wu A, Schöder H and Goodman KA: Prognostic significance of PET assessment of metabolic response to therapy in oesophageal squamous cell carcinoma. Br J Cancer. 113:1658–1665. 2015. View Article : Google Scholar : PubMed/NCBI
19	Huang JW, Yeh HL, Hsu CP, Lu YY, Chuang CY, Lin JC, Lin JF and Chang CF: To evaluate the treatment response of locally advanced esophageal cancer after preoperative chemoradiotherapy by FDG-PET/CT scan. J Chin Med Assoc. 78:229–234. 2015. View Article : Google Scholar : PubMed/NCBI
20	Myslivecek M, Neoral C, Vrba R, Vomackova K, Cincibuch J, Formanek R, Koranda P and Zapletalova J: The value of 18F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 156:171–179. 2012. View Article : Google Scholar : PubMed/NCBI
21	Adams MC, Turkington TG, Wilson JM and Wong TZ: A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol. 195:310–320. 2010. View Article : Google Scholar : PubMed/NCBI
22	Lemarignier C, Di Fiore F, Marre C, Hapdey S, Modzelewski R, Gouel P, Michel P, Dubray B and Vera P: Pretreatment metabolic tumour volume is predictive of disease-free survival and overall survival in patients with oesophageal squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 41:2008–2016. 2014. View Article : Google Scholar : PubMed/NCBI
23	Chang S, Koo PJ, Kwak JJ and Kim SJ: Changes in total lesion glycolysis evaluated by repeated F-18 FDG PET/CT as prognostic factor in locally advanced esophageal cancer patients treated with preoperative chemoradiotherapy. Oncology. 90:97–102. 2016. View Article : Google Scholar : PubMed/NCBI
24	Roedl JB, Colen RR, Holalkere NS, Fischman AJ, Choi NC and Blake MA: Adenocarcinomas of the esophagus: Response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT. Comparison to histopathologic and clinical response evaluation. Radiother Oncol. 89:278–286. 2008. View Article : Google Scholar : PubMed/NCBI
25	Palie O, Michel P, Ménard JF, Rousseau C, Rio E, Bridji B, Benyoucef A, Meyer ME, Jalali K, Bardet S, et al: The predictive value of treatment response using FDG PET performed on day 21 of chemoradiotherapy in patients with oesophageal squamous cell carcinoma. A prospective, multicentre study (RTEP3). Eur J Nucl Med Mol Imaging. 40:1345–1355. 2013. View Article : Google Scholar : PubMed/NCBI
26	Shi XH: Advances on esophageal carcinoma radiotherapy in China. China Oncol. 2001.
27	Lloyd S and Chang BW: Current strategies in chemoradiation for esophageal cancer. J Gastrointest Oncol. 5:156–165. 2014.PubMed/NCBI
28	Arslan N, Miller TR, Dehdashti F, Battafarano RJ and Siegel BA: Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography in patients with esophageal cancer. Mol Imaging Biol. 4:301–310. 2002. View Article : Google Scholar : PubMed/NCBI
29	Yue J, Chen L, Cabrera AR, Sun X, Zhao S, Zheng F, Han A, Zheng J, Teng X, Ma L, et al: Measuring tumor cell proliferation with 18F-FLT PET during radiotherapy of esophageal squamous cell carcinoma: A pilot clinical study. J Nucl Med. 51:528–534. 2010. View Article : Google Scholar : PubMed/NCBI